<p>AngioDynamics, Inc.（纳斯达克代码：ANGO - 获取免费报告）在周一的交易中，股价突破了其 200 日移动平均线。该股票的 200 日移动平均线为 9.88 美元，最高交易价为 11.95 美元。AngioDynamics 的股票最后交易价为 11.82 美元，成交量为 396,477 股。</p>
<p>获取 <strong>AngioDynamics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司进行了评论。HC Wainwright 在 7 月 16 日的研究报告中重申了对 AngioDynamics 的 “买入” 评级，并给出了 16.00 美元的目标价。Canaccord Genuity Group 将 AngioDynamics 的目标价从 17.00 美元上调至 18.00 美元，并在 10 月 3 日的研究报告中给予该公司 “买入” 评级。Wall Street Zen 在 10 月 4 日的研究报告中将 AngioDynamics 的评级从 “买入” 下调至 “持有”。Lake Street Capital 在 7 月 16 日的研究报告中开始覆盖 AngioDynamics，给予 “买入” 评级和 24.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 AngioDynamics 的 “卖出（d-）” 评级。三位股票研究分析师对该股票给予了 “买入” 评级，一位分析师则给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 19.33 美元。</p>
<p><strong>查看我们对 AngioDynamics 的最新分析</strong></p>
<h2>AngioDynamics 股票上涨 2.4%</h2>
<p>该股票的市值为 4.8698 亿美元，市盈率为-15.15，贝塔值为 0.78。该公司有 50 日简单移动平均线为 10.53 美元，200 日简单移动平均线为 9.88 美元。</p>
<p>AngioDynamics（纳斯达克代码：ANGO - 获取免费报告）最近在 10 月 2 日公布了其财报。这家医疗器械供应商报告本季度每股收益（EPS）为-0.10 美元，超出分析师一致预期的-0.12 美元，超出幅度为 0.02 美元。AngioDynamics 的股本回报率为-3.16%，净利润率为-10.67%。该公司本季度的收入为 7571 万美元，而分析师预期为 7269 万美元。去年同期，该公司的每股收益为-0.11 美元。该公司的收入同比增长 12.1%。AngioDynamics 已将其 2026 财年的指导目标设定为每股收益-0.330 至-0.230 美元。分析师平均预测 AngioDynamics, Inc.在当前财年将发布每股收益-0.37 美元。</p>
<h2>AngioDynamics 的内部买卖情况</h2>
<p>在其他 AngioDynamics 的新闻中，首席执行官 James C. Clemmer 在 10 月 9 日的交易中购买了 10,000 股 AngioDynamics 股票。该股票的平均购买成本为每股 11.15 美元，总价值为 111,500.00 美元。交易完成后，首席执行官持有该公司 882,529 股股票，价值为 9,840,198.35 美元。此次交易使其持股比例增加了 1.15%。该收购在向证券交易委员会提交的文件中披露，文件可通过此链接访问。公司内部人士持有该公司 6.00% 的股票。</p>
<h2>机构投资者对 AngioDynamics 的看法</h2>
<p>几家对冲基金最近调整了对该公司的持股。Squarepoint Ops LLC 在第二季度将其在 AngioDynamics 的持股增加了 28.3%。Squarepoint Ops LLC 目前持有 85,696 股医疗器械供应商的股票，价值为 850,000 美元，此前在该期间内又购买了 18,879 股。怀俄明州购买了 AngioDynamics 的新股份，价值约为 31,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 AngioDynamics 的持股增加了 359.0%。Tower Research Capital LLC TRC 目前持有 5,457 股医疗器械供应商的股票，价值为 54,000 美元，此前在上个季度又购买了 4,268 股。Manatuck Hill Partners LLC 在第二季度将其在 AngioDynamics 的持股增加了 7.7%。Manatuck Hill Partners LLC 目前持有 350,000 股医疗器械供应商的股票，价值为 3,472,000 美元，此前在上个季度又购买了 25,000 股。最后，Massar Capital Management LP 在第二季度收购了 AngioDynamics 的新股份，价值为 278,000 美元。89.43% 的股票由机构投资者持有。</p>
<h2>关于 AngioDynamics</h2>
<p>（获取免费报告）</p>
<p>AngioDynamics, Inc.是一家医疗技术公司，专注于设计、制造和销售用于治疗外周血管疾病、肿瘤和外科环境的医疗、外科和诊断设备。该公司提供的 Auryon 动脉切除系统旨在提供优化的波长、脉冲宽度和幅度，以去除病变，同时保护血管壁内皮。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 AngioDynamics 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>初学者如何阅读股票图表</li>
<li>3 只高收益银行供投资者在下跌时购买</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 AngioDynamics 吗？</h2>
<p>在考虑 AngioDynamics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AngioDynamics 并不在名单上。</p>
<p>虽然 AngioDynamics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿吉奥动态

<p>AngioDynamics（纳斯达克代码：ANGO）股票已超过其 200 日移动平均线，交易价格为 11.82 美元。分析师的评级不一，HC Wainwright 维持 “买入” 评级，目标价为 16.00 美元，而 Weiss Ratings 则给出了 “卖出” 评级。该公司报告的收入同比增长 12.1%，最近的每股收益为（0.10 美元），超出预期。首席执行官 James C. Clemmer 以每股 11.15 美元购买了 10,000 股。机构投资者持有 89.43% 的股份，反映出强烈的投资兴趣。平均目标价为 19.33 美元，尽管面临当前挑战，仍显示出潜在的增长空间</p>

<p>AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.88 and traded as high as $11.95. AngioDynamics shares last traded at $11.82, with a volume of 396,477 shares changing hands.</p>
<div class="lb-trans"><p>AngioDynamics, Inc.（纳斯达克代码：ANGO - 获取免费报告）在周一的交易中，股价突破了其 200 日移动平均线。该股票的 200 日移动平均线为 9.88 美元，最高交易价为 11.95 美元。AngioDynamics 的股票最后交易价为 11.82 美元，成交量为 396,477 股。</p>
</div><p>Get <strong>AngioDynamics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>AngioDynamics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts recently commented on the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group boosted their price target on AngioDynamics from $17.00 to $18.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 3rd. Wall Street Zen cut AngioDynamics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 4th. Lake Street Capital assumed coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a &#34;buy&#34; rating and a $24.00 price target for the company. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $19.33.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司进行了评论。HC Wainwright 在 7 月 16 日的研究报告中重申了对 AngioDynamics 的 “买入” 评级，并给出了 16.00 美元的目标价。Canaccord Genuity Group 将 AngioDynamics 的目标价从 17.00 美元上调至 18.00 美元，并在 10 月 3 日的研究报告中给予该公司 “买入” 评级。Wall Street Zen 在 10 月 4 日的研究报告中将 AngioDynamics 的评级从 “买入” 下调至 “持有”。Lake Street Capital 在 7 月 16 日的研究报告中开始覆盖 AngioDynamics，给予 “买入” 评级和 24.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 AngioDynamics 的 “卖出（d-）” 评级。三位股票研究分析师对该股票给予了 “买入” 评级，一位分析师则给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 19.33 美元。</p>
</div><p><strong>View Our Latest Analysis on AngioDynamics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AngioDynamics 的最新分析</strong></p>
</div><h2>AngioDynamics Stock Up 2.4%</h2>
<div class="lb-trans"><h2>AngioDynamics 股票上涨 2.4%</h2>
</div><p>The stock has a market cap of $486.98 million, a P/E ratio of -15.15 and a beta of 0.78. The business has a 50-day simple moving average of $10.53 and a 200-day simple moving average of $9.88.</p>
<div class="lb-trans"><p>该股票的市值为 4.8698 亿美元，市盈率为-15.15，贝塔值为 0.78。该公司有 50 日简单移动平均线为 10.53 美元，200 日简单移动平均线为 9.88 美元。</p>
</div><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The firm had revenue of $75.71 million during the quarter, compared to analysts' expectations of $72.69 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The company's revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. On average, analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>AngioDynamics（纳斯达克代码：ANGO - 获取免费报告）最近在 10 月 2 日公布了其财报。这家医疗器械供应商报告本季度每股收益（EPS）为-0.10 美元，超出分析师一致预期的-0.12 美元，超出幅度为 0.02 美元。AngioDynamics 的股本回报率为-3.16%，净利润率为-10.67%。该公司本季度的收入为 7571 万美元，而分析师预期为 7269 万美元。去年同期，该公司的每股收益为-0.11 美元。该公司的收入同比增长 12.1%。AngioDynamics 已将其 2026 财年的指导目标设定为每股收益-0.330 至-0.230 美元。分析师平均预测 AngioDynamics, Inc.在当前财年将发布每股收益-0.37 美元。</p>
</div><h2>Insider Buying and Selling at AngioDynamics</h2>
<div class="lb-trans"><h2>AngioDynamics 的内部买卖情况</h2>
</div><p>In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction dated Thursday, October 9th. The stock was bought at an average cost of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer owned 882,529 shares of the company's stock, valued at $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他 AngioDynamics 的新闻中，首席执行官 James C. Clemmer 在 10 月 9 日的交易中购买了 10,000 股 AngioDynamics 股票。该股票的平均购买成本为每股 11.15 美元，总价值为 111,500.00 美元。交易完成后，首席执行官持有该公司 882,529 股股票，价值为 9,840,198.35 美元。此次交易使其持股比例增加了 1.15%。该收购在向证券交易委员会提交的文件中披露，文件可通过此链接访问。公司内部人士持有该公司 6.00% 的股票。</p>
</div><h2>Institutional Investors Weigh In On AngioDynamics</h2>
<div class="lb-trans"><h2>机构投资者对 AngioDynamics 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC boosted its position in shares of AngioDynamics by 28.3% in the second quarter. Squarepoint Ops LLC now owns 85,696 shares of the medical instruments supplier's stock valued at $850,000 after acquiring an additional 18,879 shares during the period. State of Wyoming bought a new stake in shares of AngioDynamics in the second quarter valued at approximately $31,000. Tower Research Capital LLC TRC raised its stake in shares of AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock valued at $54,000 after purchasing an additional 4,268 shares in the last quarter. Manatuck Hill Partners LLC raised its stake in shares of AngioDynamics by 7.7% in the second quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier's stock valued at $3,472,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Massar Capital Management LP acquired a new position in shares of AngioDynamics in the second quarter valued at $278,000. 89.43% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该公司的持股。Squarepoint Ops LLC 在第二季度将其在 AngioDynamics 的持股增加了 28.3%。Squarepoint Ops LLC 目前持有 85,696 股医疗器械供应商的股票，价值为 850,000 美元，此前在该期间内又购买了 18,879 股。怀俄明州购买了 AngioDynamics 的新股份，价值约为 31,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 AngioDynamics 的持股增加了 359.0%。Tower Research Capital LLC TRC 目前持有 5,457 股医疗器械供应商的股票，价值为 54,000 美元，此前在上个季度又购买了 4,268 股。Manatuck Hill Partners LLC 在第二季度将其在 AngioDynamics 的持股增加了 7.7%。Manatuck Hill Partners LLC 目前持有 350,000 股医疗器械供应商的股票，价值为 3,472,000 美元，此前在上个季度又购买了 25,000 股。最后，Massar Capital Management LP 在第二季度收购了 AngioDynamics 的新股份，价值为 278,000 美元。89.43% 的股票由机构投资者持有。</p>
</div><h2>About AngioDynamics</h2>
<div class="lb-trans"><h2>关于 AngioDynamics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.</p>
<div class="lb-trans"><p>AngioDynamics, Inc.是一家医疗技术公司，专注于设计、制造和销售用于治疗外周血管疾病、肿瘤和外科环境的医疗、外科和诊断设备。该公司提供的 Auryon 动脉切除系统旨在提供优化的波长、脉冲宽度和幅度，以去除病变，同时保护血管壁内皮。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AngioDynamics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li>
<li>How to Read Stock Charts for Beginners</li>
<li>3 High-Yield Banks for Investors to Buy on the Dip</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 AngioDynamics 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>路易威登财报显示奢侈品牛市尚未结束</li>
<li>初学者如何阅读股票图表</li>
<li>3 只高收益银行供投资者在下跌时购买</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>5 只意外受益于未来机器人热潮的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AngioDynamics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 AngioDynamics 吗？</h2>
</div><p>Before you consider AngioDynamics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AngioDynamics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AngioDynamics 并不在名单上。</p>
</div><p>While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AngioDynamics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AngioDynamics（NASDAQ:ANGO）的股价已超过 200 日移动平均线 - 现在是卖出的时候吗？